Evidence map›Paper›PMID 34858178›Full record

ArticleFrontiers in pharmacology2021

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies.

Hui Tian, Xuan Wang, Bin Lian, Xieqiao Yan, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Xue Bai and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Hui TianKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Xuan WangKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Bin LianKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Xieqiao YanKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Lu SiKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Zhihong ChiKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Xinan ShengKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Yan KongKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Lili MaoKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Xue BaiKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Bixia TangKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Siming LiKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Li ZhouKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Chuanliang CuiKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Jun GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry Education), Department of Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Peking University Cancer Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antiangiogenic therapycombination therapyimmunetherapymelanomasafety profile

Identifiers

PMID34858178
PMCPMC8630676
OpenAlexW3213147230

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.